Report: Delayed approval of BioNTech

Apparently, China wants to give preference to a self-developed mRNA vaccine instead of approving the German product from BioNTech. The Wall Street Journal quotes informed circles as saying that the approval procedure for the BioNTech preparation is currently deliberately delayed. The reason is concern about confidence in homegrown vaccines. Accelerated approval of the state-of-the-art ingredient from the West could therefore create the impression that the products from Sinopharm and Sinovac are second-class vaccines.